Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults
AIM: To evaluate the clinical efficacy and safety of antiviral drug riamilovir in patients with acute respiratory viral infections (ARVI) of non-coronavirus (SARS-CoV-2) etiology with different dosing regimens.
MATERIALS AND METHODS: The study included 150 patients with ARVI aged 18-27 years (50 patients received riamilovir in the regimen of 250 mg 3 times a day for 5 days, 50 patients received riamilovir in the off label regimen of 250 mg 5 times a day for 5 days, 50 patients received only pathogenetic treatment).
RESULTS: The use of riamilovir in both treatment regimens led to a reduction in the duration of inpatient treatment. The shortest periods of hospitalization were noted in patients who received the study drug at higher daily dosages. The use of riamilovir reduced the duration and severity of general infectious manifestations of the disease, while the shortest total duration of fever and a number of respiratory tract syndromes was registered among people who received riamilovir in the regimen of 1250 mg per day for 5 days, no adverse events were registered, additionally, 100% elimination of ARVI pathogens was noted in 1250 mg per day group.
CONCLUSION: Riamilovir has shown clinical efficacy and a good safety profile in in both treatment regimens. The dosage regimen of 1250 mg per day led to more significant clinical effects and to 100% elimination of ARVI pathogens in the study group by the 6th day of hospitalization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Terapevticheskii arkhiv - 95(2023), 11 vom: 22. Dez., Seite 930-936 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Zhdanov, K V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute respiratory infections |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 03.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.26442/00403660.2023.11.202471 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366495933 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366495933 | ||
| 003 | DE-627 | ||
| 005 | 20240108141333.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2023 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/00403660.2023.11.202471 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1247.xml |
| 035 | |a (DE-627)NLM366495933 | ||
| 035 | |a (NLM)38158948 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Zhdanov, K V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical efficiency and safety of riamilovir under various dosage regimens for treatment of acute respiratory viral infections in adults |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 03.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To evaluate the clinical efficacy and safety of antiviral drug riamilovir in patients with acute respiratory viral infections (ARVI) of non-coronavirus (SARS-CoV-2) etiology with different dosing regimens | ||
| 520 | |a MATERIALS AND METHODS: The study included 150 patients with ARVI aged 18-27 years (50 patients received riamilovir in the regimen of 250 mg 3 times a day for 5 days, 50 patients received riamilovir in the off label regimen of 250 mg 5 times a day for 5 days, 50 patients received only pathogenetic treatment) | ||
| 520 | |a RESULTS: The use of riamilovir in both treatment regimens led to a reduction in the duration of inpatient treatment. The shortest periods of hospitalization were noted in patients who received the study drug at higher daily dosages. The use of riamilovir reduced the duration and severity of general infectious manifestations of the disease, while the shortest total duration of fever and a number of respiratory tract syndromes was registered among people who received riamilovir in the regimen of 1250 mg per day for 5 days, no adverse events were registered, additionally, 100% elimination of ARVI pathogens was noted in 1250 mg per day group | ||
| 520 | |a CONCLUSION: Riamilovir has shown clinical efficacy and a good safety profile in in both treatment regimens. The dosage regimen of 1250 mg per day led to more significant clinical effects and to 100% elimination of ARVI pathogens in the study group by the 6th day of hospitalization | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute respiratory infections | |
| 650 | 4 | |a acute respiratory viral infections | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a nucleoside analogues | |
| 650 | 4 | |a riamilovir | |
| 650 | 7 | |a riamilovir |2 NLM | |
| 650 | 7 | |a F2HTG1MH2D |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Maltsev, O V |e verfasserin |4 aut | |
| 700 | 1 | |a Kasyanenko, K V |e verfasserin |4 aut | |
| 700 | 1 | |a Kozlov, K V |e verfasserin |4 aut | |
| 700 | 1 | |a Sukachev, V S |e verfasserin |4 aut | |
| 700 | 1 | |a Lvov, N I |e verfasserin |4 aut | |
| 700 | 1 | |a Sharabkhanov, V V |e verfasserin |4 aut | |
| 700 | 1 | |a Litvinov, A A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Terapevticheskii arkhiv |d 1949 |g 95(2023), 11 vom: 22. Dez., Seite 930-936 |w (DE-627)NLM000055425 |x 0040-3660 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:11 |g day:22 |g month:12 |g pages:930-936 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26442/00403660.2023.11.202471 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 11 |b 22 |c 12 |h 930-936 | ||